4-(tetrahydro-furan-3-yloxy)-cyclohexanol | 1114554-18-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(tetrahydro-furan-3-yloxy)-cyclohexanol
• 英文别名: 4-(tetrahydro-furan-3S-yloxy)-cyclohexanol；4-(oxolan-3-yloxy)cyclohexan-1-ol
• CAS: 1114554-18-5
• 化学式: C₁₀H₁₈O₃
• 分子量: 186.251
• InChiKey: VTJHORUXPVBHQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(tetrahydro-furan-3-yloxy)-cyclohexanol 生成 4-(tetrahydro-furan-3-yloxy)-cyclohexanone
  参考文献：
  名称：

  BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS

  摘要：

  本发明涉及以下式（I）的化合物 其中R 1 和A如说明书中定义的作为血清素5-HT 2a 和多巴胺D 3 受体的双调节剂，它们的制备，含有它们的药物组合物以及它们作为药物的用途。一般式（I）的化合物对多巴胺D 3 和血清素（5-羟色胺；5-HT）5-HT 2A 受体具有高亲和力，并且在治疗精神分裂症等疾病以及抑郁症、焦虑症、药物依赖、痴呆症和记忆障碍等其他疾病中具有有效性。

  公开号：

  US20090042943A1
• 作为产物：
  描述：

  4-((tetrahydrofuran-3-yl)oxy)phenol 在 铑 氢气 、 二氯甲烷 、 Sodium sulfate-III 作用下， 以 sodium hydroxide 为溶剂， 60.0 ℃ 、53.33 MPa 条件下， 反应 3.0h， 以The crude product (800 mg, 86%) was obtained as a light brown liquid的产率得到4-(tetrahydro-furan-3-yloxy)-cyclohexanol
  参考文献：
  名称：

  Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors

  摘要：

  本发明涉及公式(I)的化合物，其中R1和A的定义如规范中所述，作为血清素5-HT2a和多巴胺D3受体的双重调节剂，它们的制造，含有它们的制药组合物以及它们作为药物的用途。通式(I)的化合物具有对多巴胺D3和血清素(5-羟色胺; 5-HT) 5-HT2A受体的高亲和力，并且在治疗精神病性障碍以及其他疾病，例如抑郁症和焦虑症，药物依赖，痴呆症和记忆障碍方面具有疗效。

  公开号：

  US08097637B2

文献信息

• US8097637B2
  申请人：——

  公开号：US8097637B2

  公开（公告）日：2012-01-17
• [EN] BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS<br/>[FR] DÉRIVÉS DE BENZOYL-PIPÉRIDINE COMME MODULATEURS DOUBLES DES RÉCEPTEURS 5-HT2A ET D3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009019174A1

  公开（公告）日：2009-02-12

  The present invention relates to compounds of the general Formula (I) wherein R1 and A are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general Formula (I) have high affinity for the dopamine D3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.
• BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS
  申请人：Gobbi Luca

  公开号：US20090042943A1

  公开（公告）日：2009-02-12

  The present invention relates to compounds of formula (I) wherein R 1 and A are as defined in the specification as dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general formula (I) have high affinity for the dopamine D 3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT 2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

  本发明涉及以下式（I）的化合物 其中R 1 和A如说明书中定义的作为血清素5-HT 2a 和多巴胺D 3 受体的双调节剂，它们的制备，含有它们的药物组合物以及它们作为药物的用途。一般式（I）的化合物对多巴胺D 3 和血清素（5-羟色胺；5-HT）5-HT 2A 受体具有高亲和力，并且在治疗精神分裂症等疾病以及抑郁症、焦虑症、药物依赖、痴呆症和记忆障碍等其他疾病中具有有效性。
• Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors
  申请人：Hoffmann-La Roche Inc.

  公开号：US08097637B2

  公开（公告）日：2012-01-17

  The present invention relates to compounds of formula (I) wherein R1 and A are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general formula (I) have high affinity for the dopamine D3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

  本发明涉及公式(I)的化合物，其中R1和A的定义如规范中所述，作为血清素5-HT2a和多巴胺D3受体的双重调节剂，它们的制造，含有它们的制药组合物以及它们作为药物的用途。通式(I)的化合物具有对多巴胺D3和血清素(5-羟色胺; 5-HT) 5-HT2A受体的高亲和力，并且在治疗精神病性障碍以及其他疾病，例如抑郁症和焦虑症，药物依赖，痴呆症和记忆障碍方面具有疗效。